首页 > 最新文献

Addiction最新文献

英文 中文
Impact of study design decisions on identification of treatment initiators of medications for opioid use disorder. 研究设计决策对阿片类药物使用障碍药物治疗启动者识别的影响。
IF 5.3 1区 医学 Q1 PSYCHIATRY Pub Date : 2025-12-14 DOI: 10.1111/add.70288
Payel J Roy, Ryan Colvin, Katelin B Nickel, Rachael K Ross, Michael J Durkin, Katie J Suda, Andrew Atkinson, Anne M Butler
<p><strong>Background and aims: </strong>Comparative effectiveness research studies commonly restrict cohorts to individuals who initiate a medication and do not have evidence of prior treatment. This is particularly challenging in research on medications for opioid use disorder (MOUD) because of sporadic use or intermittent adherence. We examined the impact of different lookback windows and washout criteria to identify MOUD initiator cohorts on sample size, cohort characteristics, and misclassification of treatment initiation.</p><p><strong>Design and setting: </strong>Cohort study using the Merative™ MarketScan® Multi-State Medicaid Database (2011-2022).</p><p><strong>Participants: </strong>Medicaid-insured adults aged 18-64 with an MOUD prescription from 01/01/2022 to 12/31/2022 and a history of opioid use disorder (OUD) with at least 3 months of continuous enrollment.</p><p><strong>Measurements: </strong>We created treatment initiator cohorts with increasingly restrictive lookback windows for inclusion (6-, 12-, 24-, 36-months, all-available). During each lookback window, we required [1] continuous enrollment; [2] continuous enrollment and OUD diagnosis; or [3] continuous enrollment, OUD diagnosis, and no prior treatment with MOUD. We defined prior treatment with MOUD as: (a) ≥ 30 days use (less restrictive definition; allowed for some prior treatment); or (b) ≥ 1 day use (more restrictive definition; did not allow prior treatment). We quantified changes in cohort sample size, demographic characteristics, and proportion of prevalent use episodes misclassified as MOUD treatment initiation (gold standard: 36-month lookback window).</p><p><strong>Findings: </strong>We identified 103 794 eligible MOUD initiators (64.8% buprenorphine, 24.8% methadone, 10.4% naltrexone). Sample size of the cohorts decreased with increasingly restrictive lookback windows and washout criteria: [1] continuous enrollment (range, 96.9% for 6 months to 51.8% for 36 months); [2] continuous enrollment and less restrictive washout (range, 29.7% to 8.4%); and [3] continuous enrollment and more restrictive washout (range, 22.2% to 5.8%). All-available lookback performed similarly to a 12-month lookback. Longer lookback windows resulted in initiator cohorts with a greater proportion of individuals who were older, female, and of a minoritized race/ethnicity. The proportion of people with prevalent MOUD use misclassified as treatment initiation increased steadily with decreasing duration of lookback windows (24-, 12-, and 6-month); we observed misclassification among 16.1% to 49.2% of individuals (less restrictive washout), and 16.8% to 53.2% of individuals (more restrictive washout).</p><p><strong>Conclusions: </strong>The choice of lookback window duration and washout criteria in research on medications for opioid use disorder (MOUD) presents tradeoffs between cohort sample size, demographic characteristics, and misclassification of treatment initiation. This study offers prac
背景和目的:比较有效性研究通常将队列限制在开始使用药物且没有先前治疗证据的个体。这在阿片类药物使用障碍(mod)的药物研究中尤其具有挑战性,因为阿片类药物的使用是零星的或间歇性的。我们检查了不同的回顾窗口和洗脱标准对样本量、队列特征和治疗开始错误分类的影响。设计和设置:使用Merative™MarketScan®多州医疗补助数据库(2011-2022)的队列研究。参与者:年龄在18-64岁,在2022年1月1日至2022年12月31日期间有阿片类药物使用障碍(OUD)处方,有阿片类药物使用障碍史,连续入组至少3个月的成年人。测量方法:我们创建了治疗起始者队列,纳入的回顾性窗口越来越严格(6个月、12个月、24个月、36个月,全部可用)。在每个回顾窗口,我们要求[1]连续注册;[2]连续入组和OUD诊断;或[3]连续入组,OUD诊断,既往未接受过mod治疗。我们将既往使用mod的定义为:(a)≥30天使用(限制较少,允许一些既往治疗);或(b)≥1天使用(更严格的定义,不允许事先治疗)。我们量化了队列样本量的变化、人口统计学特征和被错误归类为mod治疗起始的流行用药事件的比例(黄金标准:36个月回顾窗口)。结果:我们确定了103794种符合条件的mod引发剂(64.8%为丁丙诺啡,24.8%为美沙酮,10.4%为纳曲酮)。随着回顾性窗口和洗脱标准的限制越来越严格,队列的样本量减少:连续入组(范围,6个月96.9%至36个月51.8%);[2]连续入组和限制性较小的洗脱组(范围,29.7%至8.4%);连续入组人数为100人,洗脱期限制更严格(范围为22.2%至5.8%)。所有可用的回顾与12个月的回顾表现相似。较长的回望窗口导致发起者队列中较大比例的个体是老年人、女性和少数民族。随着回望窗时间(24个月、12个月和6个月)的减少,普遍使用mod的人群比例稳步上升;我们观察到在16.1%至49.2%的个体(较少限制性洗脱)和16.8%至53.2%的个体(更限制性洗脱)中存在错误分类。结论:在阿片类药物使用障碍(mod)药物研究中,回顾窗口持续时间和洗脱标准的选择在队列样本量、人口统计学特征和治疗开始错误分类之间存在权衡。本研究为计划在mod中进行比较研究的研究者提供了实践指导。
{"title":"Impact of study design decisions on identification of treatment initiators of medications for opioid use disorder.","authors":"Payel J Roy, Ryan Colvin, Katelin B Nickel, Rachael K Ross, Michael J Durkin, Katie J Suda, Andrew Atkinson, Anne M Butler","doi":"10.1111/add.70288","DOIUrl":"https://doi.org/10.1111/add.70288","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background and aims: &lt;/strong&gt;Comparative effectiveness research studies commonly restrict cohorts to individuals who initiate a medication and do not have evidence of prior treatment. This is particularly challenging in research on medications for opioid use disorder (MOUD) because of sporadic use or intermittent adherence. We examined the impact of different lookback windows and washout criteria to identify MOUD initiator cohorts on sample size, cohort characteristics, and misclassification of treatment initiation.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design and setting: &lt;/strong&gt;Cohort study using the Merative™ MarketScan® Multi-State Medicaid Database (2011-2022).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Participants: &lt;/strong&gt;Medicaid-insured adults aged 18-64 with an MOUD prescription from 01/01/2022 to 12/31/2022 and a history of opioid use disorder (OUD) with at least 3 months of continuous enrollment.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Measurements: &lt;/strong&gt;We created treatment initiator cohorts with increasingly restrictive lookback windows for inclusion (6-, 12-, 24-, 36-months, all-available). During each lookback window, we required [1] continuous enrollment; [2] continuous enrollment and OUD diagnosis; or [3] continuous enrollment, OUD diagnosis, and no prior treatment with MOUD. We defined prior treatment with MOUD as: (a) ≥ 30 days use (less restrictive definition; allowed for some prior treatment); or (b) ≥ 1 day use (more restrictive definition; did not allow prior treatment). We quantified changes in cohort sample size, demographic characteristics, and proportion of prevalent use episodes misclassified as MOUD treatment initiation (gold standard: 36-month lookback window).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Findings: &lt;/strong&gt;We identified 103 794 eligible MOUD initiators (64.8% buprenorphine, 24.8% methadone, 10.4% naltrexone). Sample size of the cohorts decreased with increasingly restrictive lookback windows and washout criteria: [1] continuous enrollment (range, 96.9% for 6 months to 51.8% for 36 months); [2] continuous enrollment and less restrictive washout (range, 29.7% to 8.4%); and [3] continuous enrollment and more restrictive washout (range, 22.2% to 5.8%). All-available lookback performed similarly to a 12-month lookback. Longer lookback windows resulted in initiator cohorts with a greater proportion of individuals who were older, female, and of a minoritized race/ethnicity. The proportion of people with prevalent MOUD use misclassified as treatment initiation increased steadily with decreasing duration of lookback windows (24-, 12-, and 6-month); we observed misclassification among 16.1% to 49.2% of individuals (less restrictive washout), and 16.8% to 53.2% of individuals (more restrictive washout).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;The choice of lookback window duration and washout criteria in research on medications for opioid use disorder (MOUD) presents tradeoffs between cohort sample size, demographic characteristics, and misclassification of treatment initiation. This study offers prac","PeriodicalId":109,"journal":{"name":"Addiction","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2025-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145754889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Appetitive responses toward smoking-related stimuli in abstinence-motivated, non-deprived individuals with chronic tobacco dependence: A multi-methodological investigation. 对吸烟相关刺激的食欲反应在戒烟动机,非剥夺个体慢性烟草依赖:一项多方法调查。
IF 5.3 1区 医学 Q1 PSYCHIATRY Pub Date : 2025-12-14 DOI: 10.1111/add.70283
Franziska Motka, Haoye Tan, Seth M Levine, Sabine Vollstädt-Klein, Sarah K Danböck, Katja Bertsch, Markus H Winkler, Charlotte E Wittekind

Background and aims: Appetitive responses, such as approach biases, are thought to play a crucial role in smoking. This study aimed to compare responses toward smoking-related stimuli with responses in control conditions (e.g. non-approach or neutral stimuli) using a multi-method approach. By examining associations between response measures and with smoking-related variables, the study sought to extend understanding of their role in abstinence-motivated, non-deprived individuals with chronic tobacco dependence.

Design and setting: Cross-sectional study conducted at a university laboratory and magnetic resonance imaging (MRI) scanner in Munich, Germany.

Participants: 362 chronically smoking individuals (51.38% female; data collection: November 2019-March 2023) with moderate-to-severe tobacco dependence, enrolled in a smoking cessation study, allowed ad libitum smoking prior to assessment.

Measurements: Responses toward smoking-related stimuli were assessed using cognitive-behavioral (reaction-time-based approach biases), psychophysiological (electromyography: corrugator supercilii, zygomaticus major and orbicularis oculi for acoustic startle reflex) and neural (functional MRI: regions relevant to smoking cue-reactivity) measures. Smoking-related variables were cigarettes per day, tobacco dependence severity and craving. Split-half reliabilities were estimated for all measures.

Findings: Participants exhibited a statistically significantly attenuated acoustic startle reflex toward smoking-related versus neutral stimuli (P < 0.001, Rosenthal's r = 0.39), while no statistically significant differences emerged for other psychophysiological or cognitive-behavioral measures. Neural measures showed statistically significantly heightened reactivity toward smoking-related versus neutral stimuli in sensory and motor regions (e.g. precuneus; P < 0.001, Rosenthal's r = 0.44) but reduced activity in reward-related regions (e.g. striatum; P = 0.021, Cohen's d = 0.22). Higher craving was statistically significantly associated with stronger appetitive responses on some measures from all assessment methods (Ps ≤ 0.041), whereas greater tobacco dependence and smoking behavior were linked to reduced neural reactivity toward smoking-related stimuli (Ps ≤ 0.036). No statistically significant associations emerged between measures from different methods (factor loadings ≤ 0.145, Ps ≥ 0.076). Differences scores between conditions (rel. = -0.351 to 0.837) were generally less reliable than their individual components (rel. = 0.619 to 0.964; excluding one exception) CONCLUSIONS: Appetitive responses toward smoking-related stimuli may play a limited role in abstinence-motivated, non-deprived individuals with chronic tobacco dependence, whereas habitual motor responses could be more crucial.

背景和目的:食欲反应,如接近偏差,被认为在吸烟中起着至关重要的作用。本研究旨在采用多方法比较吸烟相关刺激与对照条件(如非接近或中性刺激)的反应。通过检查反应措施与吸烟相关变量之间的联系,该研究试图进一步了解它们在慢性烟草依赖的戒烟动机、非剥夺个体中的作用。设计和设置:横断面研究在德国慕尼黑的一所大学实验室和磁共振成像(MRI)扫描仪上进行。参与者:362名长期吸烟者(51.38%为女性;数据收集:2019年11月- 2023年3月),中度至重度烟草依赖,纳入戒烟研究,在评估前允许随意吸烟。测量:对吸烟相关刺激的反应采用认知行为(基于反应时间的方法偏差)、心理生理(肌电图:波纹肌、颧大肌和眼轮匝肌的声惊吓反射)和神经(功能MRI:与吸烟提示反应相关的区域)测量来评估。与吸烟相关的变量包括每天吸烟数、烟草依赖程度和渴望程度。估计了所有测量方法的二分信度。研究结果:受试者对吸烟相关刺激的声惊吓反射与中性刺激相比有统计学上显著的减弱
{"title":"Appetitive responses toward smoking-related stimuli in abstinence-motivated, non-deprived individuals with chronic tobacco dependence: A multi-methodological investigation.","authors":"Franziska Motka, Haoye Tan, Seth M Levine, Sabine Vollstädt-Klein, Sarah K Danböck, Katja Bertsch, Markus H Winkler, Charlotte E Wittekind","doi":"10.1111/add.70283","DOIUrl":"https://doi.org/10.1111/add.70283","url":null,"abstract":"<p><strong>Background and aims: </strong>Appetitive responses, such as approach biases, are thought to play a crucial role in smoking. This study aimed to compare responses toward smoking-related stimuli with responses in control conditions (e.g. non-approach or neutral stimuli) using a multi-method approach. By examining associations between response measures and with smoking-related variables, the study sought to extend understanding of their role in abstinence-motivated, non-deprived individuals with chronic tobacco dependence.</p><p><strong>Design and setting: </strong>Cross-sectional study conducted at a university laboratory and magnetic resonance imaging (MRI) scanner in Munich, Germany.</p><p><strong>Participants: </strong>362 chronically smoking individuals (51.38% female; data collection: November 2019-March 2023) with moderate-to-severe tobacco dependence, enrolled in a smoking cessation study, allowed ad libitum smoking prior to assessment.</p><p><strong>Measurements: </strong>Responses toward smoking-related stimuli were assessed using cognitive-behavioral (reaction-time-based approach biases), psychophysiological (electromyography: corrugator supercilii, zygomaticus major and orbicularis oculi for acoustic startle reflex) and neural (functional MRI: regions relevant to smoking cue-reactivity) measures. Smoking-related variables were cigarettes per day, tobacco dependence severity and craving. Split-half reliabilities were estimated for all measures.</p><p><strong>Findings: </strong>Participants exhibited a statistically significantly attenuated acoustic startle reflex toward smoking-related versus neutral stimuli (P < 0.001, Rosenthal's r = 0.39), while no statistically significant differences emerged for other psychophysiological or cognitive-behavioral measures. Neural measures showed statistically significantly heightened reactivity toward smoking-related versus neutral stimuli in sensory and motor regions (e.g. precuneus; P < 0.001, Rosenthal's r = 0.44) but reduced activity in reward-related regions (e.g. striatum; P = 0.021, Cohen's d = 0.22). Higher craving was statistically significantly associated with stronger appetitive responses on some measures from all assessment methods (Ps ≤ 0.041), whereas greater tobacco dependence and smoking behavior were linked to reduced neural reactivity toward smoking-related stimuli (Ps ≤ 0.036). No statistically significant associations emerged between measures from different methods (factor loadings ≤ 0.145, Ps ≥ 0.076). Differences scores between conditions (rel. = -0.351 to 0.837) were generally less reliable than their individual components (rel. = 0.619 to 0.964; excluding one exception) CONCLUSIONS: Appetitive responses toward smoking-related stimuli may play a limited role in abstinence-motivated, non-deprived individuals with chronic tobacco dependence, whereas habitual motor responses could be more crucial.</p>","PeriodicalId":109,"journal":{"name":"Addiction","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2025-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145754969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Secondary analysis of a combined harm-reduction treatment and extended-release naltrexone randomized clinical trial for alcohol use disorder: Differences across race, ethnicity and sex assigned at birth. 一项针对酒精使用障碍的联合减害治疗和缓释纳曲酮随机临床试验的二级分析:不同种族、民族和出生性别的差异
IF 5.3 1区 医学 Q1 PSYCHIATRY Pub Date : 2025-12-12 DOI: 10.1111/add.70251
Silvi C Goldstein, Nicole H Weiss, Manshu Yang, Sarah W Feldstein Ewing, Susan E Collins
<p><strong>Background and aims: </strong>In a prior randomized clinical trial (RCT), combined pharmacobehavioral harm-reduction treatment improved alcohol outcomes and physical health-related quality of life (PH-QoL). In this secondary analysis, we tested race, ethnicity and sex assigned at birth as predictors and moderators of these effects.</p><p><strong>Design: </strong>Secondary study of a four-arm RCT.</p><p><strong>Setting: </strong>Community settings serving people experiencing homelessness in the US Pacific Northwest.</p><p><strong>Participants: </strong>Adults aged 21-65 (N = 308) with alcohol use disorder (AUD) who experienced past-year homelessness.</p><p><strong>Intervention: </strong>In the parent RCT, participants were randomized to brief behavioral harm-reduction treatment for AUD + extended-release naltrexone (HaRT-A + XR-NTX); HaRT-A + placebo; HaRT-A alone, or services-as-usual control.</p><p><strong>Measurement: </strong>We tested whether baseline outcomes, trial inclusion, data missingness, treatment adherence, side effects, and treatment effects on alcohol frequency, quantity, alcohol-related harm, urinary ethyl glucuronide, and PH-QoL differed by race, ethnicity, and sex assigned at birth.</p><p><strong>Findings: </strong>Race, ethnicity and sex assigned at birth were not associated with differential trial inclusion, missingness, treatment adherence or side effects with one exception: the Multiracial/other people of color (POC) group attended fewer HaRT-A sessions than the white group (odds ratio [OR] = 0.49, p = 0.03, 95% confidence interval [CI] [0.25, 0.95]). There were no statistically significant moderators of the behavioral HaRT-A effect; however, Multiracial/other POC race (B = -3.34, p = 0.03, 95% CI [-6.35, -0.34]) and sex assigned at birth (B = 2.43, p = 0.04, 95% CI [0.14, 4.73]) moderated the XR-NTX versus placebo effect on one variable: PH-QoL. Simple slope analysis indicated the Multiracial/other POC group who received placebo showed improvement on PH-QoL (dy/dx = 2.61, p = 0.003, 95% CI [0.91, 4.31]); the XR-NTX group did not (dy/dx = -0.22, p = 0.79, 95% CI [-1.90, 1.45]). Among XR-NTX recipients, the female group (dy/dx = 2.89, p < 0.001, 95% CI [1.53, 4.25]) showed faster improvement rates than the male group (dy/dx = 1.19, p = 0.02, 95% CI [0.23, 2.16]) on PH-QoL.</p><p><strong>Conclusion: </strong>Race, ethnicity and sex assigned at birth were largely not associated with trial inclusion, data missingness, treatment adherence, side effects, or outcomes in a combined harm-reduction treatment and extended-release naltrexone randomised clinical trial for alcohol use disorder (AUD). Although Multiracial/other people of color (POC) participants attended fewer brief behavioral harm-reduction treatment for AUD sessions, they did not differ from white participants on alcohol and physical health-related quality of life outcomes. Among participants receiving extended-release naltrexone (XR-NTX), women showed greater
背景和目的:在之前的一项随机临床试验(RCT)中,药物-行为减少伤害联合治疗改善了酒精结局和身体健康相关生活质量(PH-QoL)。在这一次要分析中,我们测试了种族、民族和出生时的性别作为这些影响的预测因子和调节因子。设计:四组随机对照试验的二次研究。环境:美国太平洋西北地区为无家可归者提供服务的社区环境。参与者:年龄21-65岁的成年人(N = 308),患有酒精使用障碍(AUD),过去一年无家可归。干预:在母体RCT中,参与者随机接受AUD +缓释纳曲酮(HaRT-A + XR-NTX)的简短行为伤害减少治疗;HaRT-A +安慰剂;单独的HaRT-A,或者常规服务控制。测量:我们测试了基线结果、试验纳入、数据缺失、治疗依从性、副作用和治疗对酒精频率、数量、酒精相关危害、尿乙基葡萄糖醛酸盐和PH-QoL的影响是否因种族、民族和出生性别而异。结果:人种、民族和出生时的性别与差异试验纳入、缺失、治疗依从性或副作用无关,但有一个例外:多种族/其他肤色(POC)组参加HaRT-A疗程的人数少于白人组(优势比[or] = 0.49, p = 0.03, 95%可信区间[CI][0.25, 0.95])。行为HaRT-A效应没有显著的调节因子;然而,多种族/其他POC种族(B = -3.34, p = 0.03, 95% CI[-6.35, -0.34])和出生性别(B = 2.43, p = 0.04, 95% CI[0.14, 4.73])在一个变量:PH-QoL上调节了XR-NTX与安慰剂效应。简单斜率分析显示,接受安慰剂的多种族/其他POC组的PH-QoL有所改善(dy/dx = 2.61, p = 0.003, 95% CI [0.91, 4.31]);XR-NTX集团没有(dy / dx = -0.22, p = 0.79, 95%可信区间[-1.90,1.45])。在XR-NTX接受者中,女性组(dy/dx = 2.89, p)结论:在一项针对酒精使用障碍(AUD)的减伤治疗和缓释纳曲酮随机临床试验中,种族、民族和出生时性别与试验纳入、数据缺失、治疗依从性、副作用或结果在很大程度上无关。虽然多种族/其他有色人种(POC)参与者在AUD会议中较少参加简短的行为减少伤害治疗,但他们在酒精和身体健康相关的生活质量结果上与白人参与者没有差异。在接受延长释放纳曲酮(XR-NTX)治疗的参与者中,女性在身体健康相关的生活质量方面比男性表现出更大的改善。与白人参与者相比,接受XR-NTX的多种族/其他POC参与者的改善程度低于接受安慰剂的参与者。鉴于其事后性质和有限的权力,研究结果是假设生成。他们建议公平使用行为减少伤害治疗,以及评估AUD治疗反应的社会人口统计学差异的重要性。
{"title":"Secondary analysis of a combined harm-reduction treatment and extended-release naltrexone randomized clinical trial for alcohol use disorder: Differences across race, ethnicity and sex assigned at birth.","authors":"Silvi C Goldstein, Nicole H Weiss, Manshu Yang, Sarah W Feldstein Ewing, Susan E Collins","doi":"10.1111/add.70251","DOIUrl":"https://doi.org/10.1111/add.70251","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background and aims: &lt;/strong&gt;In a prior randomized clinical trial (RCT), combined pharmacobehavioral harm-reduction treatment improved alcohol outcomes and physical health-related quality of life (PH-QoL). In this secondary analysis, we tested race, ethnicity and sex assigned at birth as predictors and moderators of these effects.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design: &lt;/strong&gt;Secondary study of a four-arm RCT.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Setting: &lt;/strong&gt;Community settings serving people experiencing homelessness in the US Pacific Northwest.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Participants: &lt;/strong&gt;Adults aged 21-65 (N = 308) with alcohol use disorder (AUD) who experienced past-year homelessness.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Intervention: &lt;/strong&gt;In the parent RCT, participants were randomized to brief behavioral harm-reduction treatment for AUD + extended-release naltrexone (HaRT-A + XR-NTX); HaRT-A + placebo; HaRT-A alone, or services-as-usual control.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Measurement: &lt;/strong&gt;We tested whether baseline outcomes, trial inclusion, data missingness, treatment adherence, side effects, and treatment effects on alcohol frequency, quantity, alcohol-related harm, urinary ethyl glucuronide, and PH-QoL differed by race, ethnicity, and sex assigned at birth.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Findings: &lt;/strong&gt;Race, ethnicity and sex assigned at birth were not associated with differential trial inclusion, missingness, treatment adherence or side effects with one exception: the Multiracial/other people of color (POC) group attended fewer HaRT-A sessions than the white group (odds ratio [OR] = 0.49, p = 0.03, 95% confidence interval [CI] [0.25, 0.95]). There were no statistically significant moderators of the behavioral HaRT-A effect; however, Multiracial/other POC race (B = -3.34, p = 0.03, 95% CI [-6.35, -0.34]) and sex assigned at birth (B = 2.43, p = 0.04, 95% CI [0.14, 4.73]) moderated the XR-NTX versus placebo effect on one variable: PH-QoL. Simple slope analysis indicated the Multiracial/other POC group who received placebo showed improvement on PH-QoL (dy/dx = 2.61, p = 0.003, 95% CI [0.91, 4.31]); the XR-NTX group did not (dy/dx = -0.22, p = 0.79, 95% CI [-1.90, 1.45]). Among XR-NTX recipients, the female group (dy/dx = 2.89, p &lt; 0.001, 95% CI [1.53, 4.25]) showed faster improvement rates than the male group (dy/dx = 1.19, p = 0.02, 95% CI [0.23, 2.16]) on PH-QoL.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;Race, ethnicity and sex assigned at birth were largely not associated with trial inclusion, data missingness, treatment adherence, side effects, or outcomes in a combined harm-reduction treatment and extended-release naltrexone randomised clinical trial for alcohol use disorder (AUD). Although Multiracial/other people of color (POC) participants attended fewer brief behavioral harm-reduction treatment for AUD sessions, they did not differ from white participants on alcohol and physical health-related quality of life outcomes. Among participants receiving extended-release naltrexone (XR-NTX), women showed greater","PeriodicalId":109,"journal":{"name":"Addiction","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2025-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145740176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preventing gambling-related harm in adolescents (PRoGRAM-A), a secondary school-based social network intervention: Results from a pilot cluster randomised controlled trial. 预防青少年赌博相关伤害(项目a),一项以中学为基础的社会网络干预:来自一项试点集群随机对照试验的结果。
IF 5.3 1区 医学 Q1 PSYCHIATRY Pub Date : 2025-12-12 DOI: 10.1111/add.70267
Fiona Dobbie, Martine Miller, Angela Niven, Heather Wardle, Christopher Weir, Hannah Ensor, Andrew Stoddart, Dave Griffiths, Leon Noble, Richard Purves, James White

Aim: To conduct a pilot cluster randomised controlled trial (cRCT) of a gambling prevention intervention (PRoGRAM-A) among young people aged 13-15 to determine the utility of conducting a Phase III RCT assessing effectiveness and cost-effectiveness.

Design: Two-arm, pilot cluster randomised controlled trial with an embedded process evaluation, health economic scoping study and social network analysis. Six schools were identified based on Scottish Index of Multiple Deprivation and school roll size. Schools were randomised to either intervention (n = 4) or control (n = 2). The trial was delivered between October 2023 and November 2024.

Setting: Six state funded secondary schools in Scotland (four intervention, two control).

Participants: Students (intervention n = 762, and control n = 352) in secondary school year 3 (aged 13-15 years old).

Intervention and comparator: PRoGRAM-A (Preventing Gambling Related Harm in Adolescents), a peer-led social network intervention to protect young people, their friends and family members from gambling related harm (GRH). Control schools delivered their standard Personal, Social, Health and Education (PSHE) curriculum, which did not include any form of gambling education.

Measurements: The primary outcome of this study was whether progression to a full-scale Phase III cRCT was warranted, using pre-set progression criteria. These criteria sought to address uncertainties in the intervention and cRCT design with thresholds set according to a traffic light system.

Findings: All five progression criteria were met. All schools were recruited and retained in the study with minimal missing outcome data. The process evaluation indicated that PRoGRAM-A was acceptable to multiple stakeholders and delivered with fidelity to the delivery manual. The proposed primary outcome for a future Phase III cRCT was self-reported gambling participation (measured by asking about types of gambling participation 'in the last 4 weeks' and 'in the last 12 months'). This pilot study found no statictically significant differences between the control and intervention groups at follow-up.

Conclusions: The school-based gambling prevention intervention PRoGRAM-A appears to be an acceptable intervention which can be delivered with high fidelity. The trial methods were acceptable with all settings recruited and retained. Progression to a larger randomised controlled trial to test effectiveness and costs effectiveness is warranted.

目的:在13-15岁的青少年中进行赌博预防干预(a计划)的试点集群随机对照试验(cRCT),以确定进行评估有效性和成本效益的III期随机对照试验的效用。设计:两组随机对照试验,采用嵌入式过程评价、健康经济范围研究和社会网络分析。根据苏格兰多重剥夺指数和学籍规模确定了六所学校。学校随机分为干预组(n = 4)和对照组(n = 2)。试验在2023年10月和2024年11月之间交付。背景:苏格兰六所公立中学(四所干预,两所对照)。参与者:中学三年级(13-15岁)学生(干预组n = 762,对照组n = 352)。干预和比较:项目a(预防青少年赌博相关伤害),一个同伴主导的社会网络干预,以保护年轻人,他们的朋友和家人免受赌博相关伤害(GRH)。对照学校提供标准的个人、社会、健康和教育课程,其中不包括任何形式的赌博教育。测量:本研究的主要结果是使用预先设定的进展标准,是否有必要进展到全面的III期cRCT。这些标准旨在解决干预和cRCT设计中的不确定性,并根据交通灯系统设置阈值。结果:所有5项进展标准均满足。所有学校都被招募并保留在研究中,结果数据缺失最少。过程评估表明PRoGRAM-A对于多个涉众是可接受的,并且交付时忠实于交付手册。拟议的未来III期cRCT的主要结果是自我报告的赌博参与(通过询问“过去4周”和“过去12个月”的赌博参与类型来衡量)。这项初步研究在随访中发现对照组和干预组之间没有统计学上的显著差异。结论:以学校为基础的预防赌博干预项目a是一种可接受的干预措施,可以提供高保真度的干预。试验方法是可接受的,所有设置的招募和保留。有必要进行更大规模的随机对照试验,以测试有效性和成本效益。
{"title":"Preventing gambling-related harm in adolescents (PRoGRAM-A), a secondary school-based social network intervention: Results from a pilot cluster randomised controlled trial.","authors":"Fiona Dobbie, Martine Miller, Angela Niven, Heather Wardle, Christopher Weir, Hannah Ensor, Andrew Stoddart, Dave Griffiths, Leon Noble, Richard Purves, James White","doi":"10.1111/add.70267","DOIUrl":"https://doi.org/10.1111/add.70267","url":null,"abstract":"<p><strong>Aim: </strong>To conduct a pilot cluster randomised controlled trial (cRCT) of a gambling prevention intervention (PRoGRAM-A) among young people aged 13-15 to determine the utility of conducting a Phase III RCT assessing effectiveness and cost-effectiveness.</p><p><strong>Design: </strong>Two-arm, pilot cluster randomised controlled trial with an embedded process evaluation, health economic scoping study and social network analysis. Six schools were identified based on Scottish Index of Multiple Deprivation and school roll size. Schools were randomised to either intervention (n = 4) or control (n = 2). The trial was delivered between October 2023 and November 2024.</p><p><strong>Setting: </strong>Six state funded secondary schools in Scotland (four intervention, two control).</p><p><strong>Participants: </strong>Students (intervention n = 762, and control n = 352) in secondary school year 3 (aged 13-15 years old).</p><p><strong>Intervention and comparator: </strong>PRoGRAM-A (Preventing Gambling Related Harm in Adolescents), a peer-led social network intervention to protect young people, their friends and family members from gambling related harm (GRH). Control schools delivered their standard Personal, Social, Health and Education (PSHE) curriculum, which did not include any form of gambling education.</p><p><strong>Measurements: </strong>The primary outcome of this study was whether progression to a full-scale Phase III cRCT was warranted, using pre-set progression criteria. These criteria sought to address uncertainties in the intervention and cRCT design with thresholds set according to a traffic light system.</p><p><strong>Findings: </strong>All five progression criteria were met. All schools were recruited and retained in the study with minimal missing outcome data. The process evaluation indicated that PRoGRAM-A was acceptable to multiple stakeholders and delivered with fidelity to the delivery manual. The proposed primary outcome for a future Phase III cRCT was self-reported gambling participation (measured by asking about types of gambling participation 'in the last 4 weeks' and 'in the last 12 months'). This pilot study found no statictically significant differences between the control and intervention groups at follow-up.</p><p><strong>Conclusions: </strong>The school-based gambling prevention intervention PRoGRAM-A appears to be an acceptable intervention which can be delivered with high fidelity. The trial methods were acceptable with all settings recruited and retained. Progression to a larger randomised controlled trial to test effectiveness and costs effectiveness is warranted.</p>","PeriodicalId":109,"journal":{"name":"Addiction","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2025-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145740156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Could alcohol-free and low-alcohol beverages be used to extinguish alcohol cravings? 无酒精和低酒精饮料可以用来消除对酒精的渴望吗?
IF 5.3 1区 医学 Q1 PSYCHIATRY Pub Date : 2025-12-11 DOI: 10.1111/add.70295
Molly A Bowdring
{"title":"Could alcohol-free and low-alcohol beverages be used to extinguish alcohol cravings?","authors":"Molly A Bowdring","doi":"10.1111/add.70295","DOIUrl":"https://doi.org/10.1111/add.70295","url":null,"abstract":"","PeriodicalId":109,"journal":{"name":"Addiction","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2025-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145720293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring the genetic overlap between substance use disorder and educational attainment. 探索物质使用障碍和受教育程度之间的基因重叠。
IF 5.3 1区 医学 Q1 PSYCHIATRY Pub Date : 2025-12-10 DOI: 10.1111/add.70254
Judit Cabana-Domínguez, Laura Vilar-Ribó, María Soler Artigas, Silvia Alemany, Natalia Llonga, Pau Carabí-Gassol, Uxue Zubizarreta-Arruti, Valeria Macias-Chimborazo, Lara Grau-López, Constanza Daigre, Elena Ros-Cucurull, Raúl Felipe Palma-Alvarez, Germán Ortega-Hernández, Noèlia Fernàndez-Castillo, Bru Cormand, Josep Antoni Ramos-Quiroga, Marta Ribasés

Background and aims: Substance use disorder (SUD) is a polygenic psychiatric condition characterized by persistent drug use despite negative consequences. Several studies support that higher cognitive performance and educational attainment (EA) are associated with a reduced risk for SUD. Here, we aimed to understand better the genetic relationship between EA and SUD, using a general addiction risk-factor (addiction) as a proxy of SUD.

Method: We used GWAS summary statistics on EA (n = 766 345) and addiction (n = 647 703) and applied a multistep approach to: (i) examinate the genetic overlap between EA and addiction; (ii) test the polygenic contribution of addiction and EA on SUD diagnosis and its clinical heterogeneity in an independent in-house clinical sample (1427 individuals with SUD and 2309 controls); and (iii) dissect the genetic liability of addiction according to its role in EA and assessing its genetic overlap with SUD-related traits, other mental disorders and behavioral traits.

Results: We confirmed a negative genetic correlation between addiction and EA [rg = -0.33, standard error (SE) = 0.02, P = 1.14e-57]. When we dissected the genetic liability of addiction by its relationship with EA we found that the discordant overlapping variation between addiction and EA, highly enriched for the genetic background of addiction (h2 SNP = 2.42%, P = 6.37e-21), showed the strongest effect on SUD (OR = 1.66, 95% confidence interval = 1.54-1.79, P = 2.01e-40) and was associated with worse sociodemographic, health and SUD-related outcomes in individuals with SUD compared with the other genomic partitions studied.

Conclusions: Our results provide new evidence on the shared genetic basis between addiction and educational attainment. By separating the genetic liability of addiction according to its relationship with educational attainment, we were able to clarify its polygenic effects on substance use disorder diagnosis and related outcomes, providing novel insights into the shared genetic signatures between addiction and other comorbid traits.

背景和目的:物质使用障碍(SUD)是一种多基因精神疾病,其特征是持续使用药物,尽管有不良后果。一些研究支持较高的认知表现和教育程度(EA)与降低患SUD的风险相关。在这里,我们的目的是更好地了解EA和SUD之间的遗传关系,使用一般成瘾风险因素(成瘾)作为SUD的代理。方法:对EA (n = 766 345)和成瘾(n = 647 703)进行GWAS汇总统计,采用多步骤方法:(i)检查EA和成瘾之间的遗传重叠;(ii)通过独立的内部临床样本(1427名SUD患者和2309名对照组)检验成瘾和EA对SUD诊断的多基因贡献及其临床异质性;(iii)根据成瘾在EA中的作用,分析成瘾的遗传责任,并评估其与sud相关特征、其他精神障碍和行为特征的遗传重叠。结果:我们证实了成瘾与EA之间的负遗传相关[rg = -0.33,标准误差(SE) = 0.02, P = 1.14e-57]。当我们通过成瘾与EA的关系来分析成瘾的遗传倾向时,我们发现成瘾与EA之间的不一致重叠变异,高度丰富了成瘾的遗传背景(h2 SNP = 2.42%, P = 6.37e-21),对SUD的影响最大(OR = 1.66, 95%置信区间= 1.54-1.79,P = 2.01e-40),与其他基因组分区相比,SUD患者的社会人口统计学、健康和SUD相关结果更差。结论:我们的研究结果为成瘾与受教育程度之间的共同遗传基础提供了新的证据。通过根据成瘾与受教育程度的关系分离成瘾的遗传倾向,我们能够阐明其对物质使用障碍诊断和相关结果的多基因影响,为成瘾和其他共病特征之间的共同遗传特征提供新的见解。
{"title":"Exploring the genetic overlap between substance use disorder and educational attainment.","authors":"Judit Cabana-Domínguez, Laura Vilar-Ribó, María Soler Artigas, Silvia Alemany, Natalia Llonga, Pau Carabí-Gassol, Uxue Zubizarreta-Arruti, Valeria Macias-Chimborazo, Lara Grau-López, Constanza Daigre, Elena Ros-Cucurull, Raúl Felipe Palma-Alvarez, Germán Ortega-Hernández, Noèlia Fernàndez-Castillo, Bru Cormand, Josep Antoni Ramos-Quiroga, Marta Ribasés","doi":"10.1111/add.70254","DOIUrl":"https://doi.org/10.1111/add.70254","url":null,"abstract":"<p><strong>Background and aims: </strong>Substance use disorder (SUD) is a polygenic psychiatric condition characterized by persistent drug use despite negative consequences. Several studies support that higher cognitive performance and educational attainment (EA) are associated with a reduced risk for SUD. Here, we aimed to understand better the genetic relationship between EA and SUD, using a general addiction risk-factor (addiction) as a proxy of SUD.</p><p><strong>Method: </strong>We used GWAS summary statistics on EA (n = 766 345) and addiction (n = 647 703) and applied a multistep approach to: (i) examinate the genetic overlap between EA and addiction; (ii) test the polygenic contribution of addiction and EA on SUD diagnosis and its clinical heterogeneity in an independent in-house clinical sample (1427 individuals with SUD and 2309 controls); and (iii) dissect the genetic liability of addiction according to its role in EA and assessing its genetic overlap with SUD-related traits, other mental disorders and behavioral traits.</p><p><strong>Results: </strong>We confirmed a negative genetic correlation between addiction and EA [r<sub>g</sub> = -0.33, standard error (SE) = 0.02, P = 1.14e-57]. When we dissected the genetic liability of addiction by its relationship with EA we found that the discordant overlapping variation between addiction and EA, highly enriched for the genetic background of addiction (h<sup>2</sup> <sub>SNP</sub> = 2.42%, P = 6.37e-21), showed the strongest effect on SUD (OR = 1.66, 95% confidence interval = 1.54-1.79, P = 2.01e-40) and was associated with worse sociodemographic, health and SUD-related outcomes in individuals with SUD compared with the other genomic partitions studied.</p><p><strong>Conclusions: </strong>Our results provide new evidence on the shared genetic basis between addiction and educational attainment. By separating the genetic liability of addiction according to its relationship with educational attainment, we were able to clarify its polygenic effects on substance use disorder diagnosis and related outcomes, providing novel insights into the shared genetic signatures between addiction and other comorbid traits.</p>","PeriodicalId":109,"journal":{"name":"Addiction","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2025-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145720240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) for alcohol use disorder: An open-label, phase 2, proof-of-concept, clinical trial. 5-甲氧基- n, n-二甲基色胺(5-MeO-DMT)治疗酒精使用障碍:一项开放标签、2期、概念验证的临床试验
IF 5.3 1区 医学 Q1 PSYCHIATRY Pub Date : 2025-12-10 DOI: 10.1111/add.70260
John Marsden, Michael Kelleher, Fiona Dunbar, Anna O Ermakova, Luke Mitcheson, Claire Roberts, James J Rucker, Gemma Scott, Ivan Saeger, Francesca Small, Mathieu Seynaeve
<p><strong>Background and aims: </strong>Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL-003, a novel intranasal powder formulation of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) benzoate salt, in people with moderate-severe AUD enrolled in a standard of care, 10-week programme of relapse-prevention oriented Cognitive Behavioural Therapy (CBT).</p><p><strong>Design: </strong>Open-label, phase 2a, single-dose, clinical trial with 12-week follow-up (Day 84 endpoint) with a target of 12 participants.</p><p><strong>Setting: </strong>Two clinics in England between 29 March 2023 and 2 July 2024.</p><p><strong>Participants: </strong>Thirteen participants were enrolled. Most were male (n = 10; 76.9%), of White-UK origin (n = 12; 92.3%), with a mean age of 49.3 years. Twelve participants completed the study (efficacy analysis set).</p><p><strong>Intervention: </strong>Participants received a single intranasal dose of 10 mg BPL-003 in a controlled environment with psychological support. Participants received three pre-dose preparation sessions and three post-dose integration sessions before CBT.</p><p><strong>Measurements: </strong>Primary endpoints were safety and tolerability (by physical examination, laboratory evaluations, cardiac telemetry and treatment emergent adverse events [TEAEs]). Exploratory endpoints included Timeline Follow-Back recording of alcohol use (abstinent days, units per day/week, heavy drinking days [HDDs; defined according to the UK government definition of binge drinking: ≥7 units per day women, ≥9 units per day men]) to Week 12 follow-up (study endpoint); craving, alcohol-related problems; and patient- and clinician-reported measures of well-being and health-related quality of life (HRQoL).</p><p><strong>Findings: </strong>Over 12 weeks, 41 TEAEs (all mild or moderate in severity) were reported by 11 of 12 (84.6%) participants (no TEAE-related withdrawals). The most common TEAEs were study drug administration site pain (four participants; 30.8%); transient elevations in blood pressure after drug administration (four participants; 30.8%); and flashbacks (reactivations), nightmares, and nausea (two participants; 15.4%). At Week 12, the mean (standard deviation [SD]) percentage of abstinent days increased from 33.2% (22.8) at baseline to 80.8% (28.2) and HDDs reduced from 56.2% (SD 26.4) at baseline to 13.2% (SD 21.8). Six of 12 participants (50%) were continuously abstinent, three (25%) had meaningful reductions in alcohol consumption, and three (25%) had no change or a limited change in their drinking patterns. Overall, measures of the negative consequences of alcohol, craving, well-being and HRQoL indicated improvement.</p><p><strong>Conclusions: </strong>A first phase 2a clinical trial of 5-methoxy-N,N-dimethyltryptamine (BPL-003 10 mg) in the context of a 10-week programme of CBT demonstrated acceptable safety and tolerability and provided preliminary evidence of efficacy for reducing alco
背景和目的:致幻剂可能有助于治疗酒精使用障碍(AUD)。本研究评估了bpl003,一种新型的5-甲氧基- n, n -二甲基色胺(5-MeO-DMT)苯甲酸盐鼻内粉状制剂,用于中重度AUD患者,该患者参加了为期10周的标准护理以预防复发为导向的认知行为疗法(CBT)。设计:开放标签,2a期,单剂量,12周随访的临床试验(第84天终点),目标12名参与者。地点:2023年3月29日至2024年7月2日在英格兰的两个诊所。参与者:共纳入13名参与者。多数为男性(n = 10,占76.9%),白人-英国血统(n = 12,占92.3%),平均年龄49.3岁。12名参与者完成了研究(疗效分析集)。干预:参与者在有心理支持的受控环境中接受单次鼻内剂量10mg BPL-003。参与者在CBT前接受了三次剂量前准备和三次剂量后整合。测量:主要终点是安全性和耐受性(通过体格检查、实验室评估、心脏遥测和治疗紧急不良事件[teae])。探索性终点包括酒精使用的时间轴回返记录(戒酒天数、每天/每周单位、重度饮酒天数[hdd;根据英国政府对酗酒的定义:女性每天≥7单位,男性每天≥9单位])至第12周随访(研究终点);渴望、酒精相关问题;以及患者和临床医生报告的幸福感和健康相关生活质量(HRQoL)指标。研究结果:在12周内,12名参与者中有11名(84.6%)报告了41例teae(均为轻度或中度严重程度)(无teae相关戒断)。最常见的teae是研究给药部位疼痛(4名参与者,30.8%);给药后血压一过性升高(4例,30.8%);以及闪回(再激活)、噩梦和恶心(2名参与者;15.4%)。在第12周,平均(标准差[SD])禁欲天数百分比从基线的33.2%(22.8)增加到80.8% (28.2),hdd从基线的56.2% (SD 26.4)减少到13.2% (SD 21.8)。12名参与者中有6人(50%)持续戒酒,3人(25%)的饮酒量有明显减少,3人(25%)的饮酒模式没有改变或改变有限。总体而言,对酒精、渴望、幸福感和HRQoL的负面影响的测量表明,情况有所改善。结论:在为期10周的CBT治疗中,5-甲氧基- n, n -二甲基色胺(bdl -003 10 mg)的第一2a期临床试验显示出可接受的安全性和耐受性,并提供了减少酒精渴望和消费的初步证据。这些发现支持对BPL-003治疗酒精使用障碍进行更大规模的对照试验。
{"title":"5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) for alcohol use disorder: An open-label, phase 2, proof-of-concept, clinical trial.","authors":"John Marsden, Michael Kelleher, Fiona Dunbar, Anna O Ermakova, Luke Mitcheson, Claire Roberts, James J Rucker, Gemma Scott, Ivan Saeger, Francesca Small, Mathieu Seynaeve","doi":"10.1111/add.70260","DOIUrl":"https://doi.org/10.1111/add.70260","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background and aims: &lt;/strong&gt;Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL-003, a novel intranasal powder formulation of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) benzoate salt, in people with moderate-severe AUD enrolled in a standard of care, 10-week programme of relapse-prevention oriented Cognitive Behavioural Therapy (CBT).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design: &lt;/strong&gt;Open-label, phase 2a, single-dose, clinical trial with 12-week follow-up (Day 84 endpoint) with a target of 12 participants.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Setting: &lt;/strong&gt;Two clinics in England between 29 March 2023 and 2 July 2024.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Participants: &lt;/strong&gt;Thirteen participants were enrolled. Most were male (n = 10; 76.9%), of White-UK origin (n = 12; 92.3%), with a mean age of 49.3 years. Twelve participants completed the study (efficacy analysis set).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Intervention: &lt;/strong&gt;Participants received a single intranasal dose of 10 mg BPL-003 in a controlled environment with psychological support. Participants received three pre-dose preparation sessions and three post-dose integration sessions before CBT.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Measurements: &lt;/strong&gt;Primary endpoints were safety and tolerability (by physical examination, laboratory evaluations, cardiac telemetry and treatment emergent adverse events [TEAEs]). Exploratory endpoints included Timeline Follow-Back recording of alcohol use (abstinent days, units per day/week, heavy drinking days [HDDs; defined according to the UK government definition of binge drinking: ≥7 units per day women, ≥9 units per day men]) to Week 12 follow-up (study endpoint); craving, alcohol-related problems; and patient- and clinician-reported measures of well-being and health-related quality of life (HRQoL).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Findings: &lt;/strong&gt;Over 12 weeks, 41 TEAEs (all mild or moderate in severity) were reported by 11 of 12 (84.6%) participants (no TEAE-related withdrawals). The most common TEAEs were study drug administration site pain (four participants; 30.8%); transient elevations in blood pressure after drug administration (four participants; 30.8%); and flashbacks (reactivations), nightmares, and nausea (two participants; 15.4%). At Week 12, the mean (standard deviation [SD]) percentage of abstinent days increased from 33.2% (22.8) at baseline to 80.8% (28.2) and HDDs reduced from 56.2% (SD 26.4) at baseline to 13.2% (SD 21.8). Six of 12 participants (50%) were continuously abstinent, three (25%) had meaningful reductions in alcohol consumption, and three (25%) had no change or a limited change in their drinking patterns. Overall, measures of the negative consequences of alcohol, craving, well-being and HRQoL indicated improvement.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;A first phase 2a clinical trial of 5-methoxy-N,N-dimethyltryptamine (BPL-003 10 mg) in the context of a 10-week programme of CBT demonstrated acceptable safety and tolerability and provided preliminary evidence of efficacy for reducing alco","PeriodicalId":109,"journal":{"name":"Addiction","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2025-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145712611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rare but relevant: MDMA and hyponatraemia. 罕见但相关:MDMA和低钠血症。
IF 5.3 1区 医学 Q1 PSYCHIATRY Pub Date : 2025-12-08 DOI: 10.1111/add.70255
Maria Rita Garcia, Nelson G M Gomes, Diana Dias-da-Silva

Conventionally used for its stimulant, empathogenic and entactogenic effects, 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) is one of the most commonly used psychoactive drugs, specifically among young adults and in nightlife and recreational party contexts. Often perceived as a safe drug, MDMA can display an array of toxic effects on multiple organs, with hyponatraemia (a low blood sodium concentration that can cause an altered mental state) being increasingly reported. Although hyponatraemia per se is among the most common electrolyte disorders encountered in clinical care, acute MDMA-induced hyponatraemia was first described in 1993 and constitutes a life-threatening condition if left untreated, particularly among women, who present higher incidence rates and increased odds of developing severe clinical effects. The present review outlines the main clinical manifestations and prevalence of MDMA-induced hyponatraemia, its pathophysiological mechanisms and the therapeutical approaches to correct this electrolyte imbalance.

3,4-亚甲基二氧甲基苯丙胺(MDMA,摇头丸)通常因其兴奋、致病性和致幻作用而被使用,是最常用的精神活性药物之一,特别是在年轻人中,以及在夜生活和娱乐派对环境中。MDMA通常被认为是一种安全的药物,但它可以对多个器官产生一系列毒性作用,低钠血症(低血钠浓度可导致精神状态改变)的报道越来越多。虽然低钠血症本身是临床护理中最常见的电解质紊乱之一,但mdma引起的急性低钠血症在1993年首次被描述,如果不及时治疗,将构成危及生命的疾病,特别是在妇女中,她们的发病率更高,发生严重临床反应的几率也更大。本文概述了mdma诱导的低钠血症的主要临床表现和流行情况,其病理生理机制和纠正这种电解质失衡的治疗方法。
{"title":"Rare but relevant: MDMA and hyponatraemia.","authors":"Maria Rita Garcia, Nelson G M Gomes, Diana Dias-da-Silva","doi":"10.1111/add.70255","DOIUrl":"https://doi.org/10.1111/add.70255","url":null,"abstract":"<p><p>Conventionally used for its stimulant, empathogenic and entactogenic effects, 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) is one of the most commonly used psychoactive drugs, specifically among young adults and in nightlife and recreational party contexts. Often perceived as a safe drug, MDMA can display an array of toxic effects on multiple organs, with hyponatraemia (a low blood sodium concentration that can cause an altered mental state) being increasingly reported. Although hyponatraemia per se is among the most common electrolyte disorders encountered in clinical care, acute MDMA-induced hyponatraemia was first described in 1993 and constitutes a life-threatening condition if left untreated, particularly among women, who present higher incidence rates and increased odds of developing severe clinical effects. The present review outlines the main clinical manifestations and prevalence of MDMA-induced hyponatraemia, its pathophysiological mechanisms and the therapeutical approaches to correct this electrolyte imbalance.</p>","PeriodicalId":109,"journal":{"name":"Addiction","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2025-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145706719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Variations in US county-level trends in buprenorphine use, 2018-2022. 2018-2022年美国丁丙诺啡使用趋势变化
IF 5.3 1区 医学 Q1 PSYCHIATRY Pub Date : 2025-12-07 DOI: 10.1111/add.70264
Taylor W Lefler, Grace Chai, Sonal Goyal, Jaejoon Song, Jing Xu, Lisa T Weissburg, Monica A Muñoz, Gerald Dal Pan

Background and aims: Despite multiple interventions, national-level trends of buprenorphine prescription use plateaued during a period of increasing opioid overdose deaths in the United States; county-level use trends may provide additional insights. We aimed to analyze county-level trends in buprenorphine treatment for opioid use disorder (OUD) and determine factors associated with trends.

Design: In this retrospective study, we used an iterative hierarchical cluster analysis to group counties with similar buprenorphine prescription use trends and then compared characteristics between clusters.

Setting: Retail pharmacy dispensing in the United States from 2018 to 2022.

Participants: Data on prescriptions dispensed for buprenorphine medications labeled to treat OUD.

Measurements: We analyzed standardized mean differences (SMD) and 95% confidence intervals (CI) of county-level characteristics between counties with varying trends in buprenorphine utilization.

Findings: Prescriptions dispensed for buprenorphine significantly increased in 924 counties (28% of US population) from 2018 to 2022 but declined in 839 counties (50%) from 2021 to 2022. Counties with decreasing (versus increasing) use had significantly higher opioid overdose death rates (SMD = -0.23; 95% CI = -0.34 to -0.13) and unemployment (SMD = -0.36; 95% CI = -0.46 to -0.27). Counties with increasing trends had higher percentages of residents in rural areas (SMD = 0.26; 95% CI = 0.16-0.35) and prescribing by nurse practitioners (SMD = 0.39; 95% CI = 0.29-0.48).

Conclusions: From 2018 to 2022, buprenorphine use as treatment for opioid use disorder increased in some United States counties, notably counties with more residents living in rural areas and counties with more prescriptions written by nurse practitioners. However, declining use in other US counties suggest challenges persist in increasing access to medication for treament of opioid use disorder, hindering progress in addressing the opioid crisis.

背景和目的:尽管有多种干预措施,在美国阿片类药物过量死亡增加期间,丁丙诺啡处方使用的国家级趋势趋于稳定;县级的使用趋势可能会提供更多的见解。我们的目的是分析县级丁丙诺啡治疗阿片类药物使用障碍(OUD)的趋势,并确定与趋势相关的因素。设计:在这项回顾性研究中,我们使用迭代分层聚类分析对丁丙诺啡处方使用趋势相似的县进行分组,然后比较聚类之间的特征。设定:2018 - 2022年美国零售药房配药市场。参与者:用于治疗OUD的丁丙诺啡药物的处方数据。测量方法:我们分析了丁丙诺啡使用趋势不同的县之间的标准化平均差异(SMD)和95%置信区间(CI)。从2018年到2022年,924个县(占美国人口的28%)的丁丙诺啡处方数量显著增加,但从2021年到2022年,839个县(50%)的丁丙诺啡处方数量下降。减少(相对于增加)使用阿片类药物的县,阿片类药物过量死亡率(SMD = -0.23; 95% CI = -0.34至-0.13)和失业率(SMD = -0.36; 95% CI = -0.46至-0.27)显著较高。呈上升趋势的县农村居民比例较高(SMD = 0.26, 95% CI = 0.16-0.35),执业护士处方比例较高(SMD = 0.39, 95% CI = 0.29-0.48)。结论:2018 - 2022年,丁丙诺啡用于阿片类药物使用障碍的治疗在美国一些县有所增加,尤其是农村人口较多的县和执业护士处方较多的县。然而,美国其他县的使用量下降表明,在增加阿片类药物使用障碍治疗药物的可及性方面仍然存在挑战,阻碍了解决阿片类药物危机的进展。
{"title":"Variations in US county-level trends in buprenorphine use, 2018-2022.","authors":"Taylor W Lefler, Grace Chai, Sonal Goyal, Jaejoon Song, Jing Xu, Lisa T Weissburg, Monica A Muñoz, Gerald Dal Pan","doi":"10.1111/add.70264","DOIUrl":"10.1111/add.70264","url":null,"abstract":"<p><strong>Background and aims: </strong>Despite multiple interventions, national-level trends of buprenorphine prescription use plateaued during a period of increasing opioid overdose deaths in the United States; county-level use trends may provide additional insights. We aimed to analyze county-level trends in buprenorphine treatment for opioid use disorder (OUD) and determine factors associated with trends.</p><p><strong>Design: </strong>In this retrospective study, we used an iterative hierarchical cluster analysis to group counties with similar buprenorphine prescription use trends and then compared characteristics between clusters.</p><p><strong>Setting: </strong>Retail pharmacy dispensing in the United States from 2018 to 2022.</p><p><strong>Participants: </strong>Data on prescriptions dispensed for buprenorphine medications labeled to treat OUD.</p><p><strong>Measurements: </strong>We analyzed standardized mean differences (SMD) and 95% confidence intervals (CI) of county-level characteristics between counties with varying trends in buprenorphine utilization.</p><p><strong>Findings: </strong>Prescriptions dispensed for buprenorphine significantly increased in 924 counties (28% of US population) from 2018 to 2022 but declined in 839 counties (50%) from 2021 to 2022. Counties with decreasing (versus increasing) use had significantly higher opioid overdose death rates (SMD = -0.23; 95% CI = -0.34 to -0.13) and unemployment (SMD = -0.36; 95% CI = -0.46 to -0.27). Counties with increasing trends had higher percentages of residents in rural areas (SMD = 0.26; 95% CI = 0.16-0.35) and prescribing by nurse practitioners (SMD = 0.39; 95% CI = 0.29-0.48).</p><p><strong>Conclusions: </strong>From 2018 to 2022, buprenorphine use as treatment for opioid use disorder increased in some United States counties, notably counties with more residents living in rural areas and counties with more prescriptions written by nurse practitioners. However, declining use in other US counties suggest challenges persist in increasing access to medication for treament of opioid use disorder, hindering progress in addressing the opioid crisis.</p>","PeriodicalId":109,"journal":{"name":"Addiction","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2025-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145699597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The changing face of nicotine use in England: Age-specific annual trends, 2014 to 2024. 英国尼古丁使用的变化面貌:2014年至2024年特定年龄的年度趋势。
IF 5.3 1区 医学 Q1 PSYCHIATRY Pub Date : 2025-12-07 DOI: 10.1111/add.70243
Sarah E Jackson, Lion Shahab, Vera Buss, Harry Tattan-Birch, Sharon Cox, Eve Taylor, Jamie Brown

Aims: To examine age-specific trends in patterns of nicotine use in England between 2014 and 2024, including types of products used, exclusive and dual use of smoking and vaping, smoking frequency and the smoking history of those who vape.

Design: Repeat monthly cross-sectional analysis of data from a nationally representative survey (the Smoking Toolkit Study).

Setting: England, 2014-2024.

Participants: 217 433 adults (≥18y).

Measurements: Prevalence of (non-medicinal) nicotine use overall and by product type (combustible tobacco, e-cigarettes, heated tobacco products and nicotine pouches), exclusive and dual use of smoking and vaping, daily versus non-daily smoking and smoking history among those who vape. Estimates were stratified by age group (18-24, 25-34, 35-44, 45-54, 55-64, ≥65y) and year. Prevalence ratios (PR) with 95% confidence intervals (CI) were calculated to quantify relative changes in prevalence from 2014 to 2024.

Findings: Nicotine use patterns varied markedly by age. Among 18-24-year-olds, vaping prevalence increased fivefold, from 5.0% in 2014 to 25.0% in 2024 (PR = 5.00; 95% CI = 4.18-5.91), surpassing smoking by 2023. This contributed to an overall increase in nicotine use (26.1% to 36.5%; PR = 1.40; 95% CI = 1.29-1.53), despite declining smoking rates (25.3% to 19.9%; PR = 0.79; 95% CI = 0.71-0.88). In this age group, exclusive vaping became the most common mode of nicotine use, while nicotine pouch use also increased. Daily smoking declined substantially among 18-24-year-olds who smoked, with a shift toward non-daily smoking. Similar trends were observed among adults aged 25-44, though changes were smaller with increasing age. In older age groups (≥45), daily smoking declined modestly while vaping rose gradually, but there was little overall change in the prevalence of nicotine use. Most adults who vaped had a history of smoking, but the proportion who had never regularly smoked increased, particularly among 18-24-year-olds (4.3% to 34.3%; PR = 7.98; 95% CI = 4.56-26.2).

Conclusions: Generational shifts in nicotine use are occurring in England. Nicotine use has risen among young adults over the past decade, but they are increasingly moving away from daily cigarette smoking towards vaping or non-daily smoking. While older adults have also shown movement away from daily smoking, traditional smoking patterns remain more prevalent in this group. These trends suggest vaping may gradually replace smoking as the dominant form of nicotine consumption.

目的:研究2014年至2024年间英国尼古丁使用模式的年龄特定趋势,包括使用的产品类型、吸烟和电子烟的专用和双重用途、吸烟频率和电子烟使用者的吸烟史。设计:每月重复一次全国代表性调查(吸烟工具包研究)数据的横断面分析。背景:英国,2014-2024年。参与者:217433名成人(≥18岁)。测量方法:总体和按产品类型(可燃烟草、电子烟、加热烟草制品和尼古丁袋)的(非药用)尼古丁使用的流行程度,吸烟和电子烟的专用和双重用途,每日吸烟与非每日吸烟,以及电子烟使用者的吸烟史。评估结果按年龄组(18-24岁、25-34岁、35-44岁、45-54岁、55-64岁、≥65岁)和年龄分层。计算患病率比(PR)和95%置信区间(CI),以量化2014年至2024年患病率的相对变化。研究发现:尼古丁的使用模式因年龄的不同而有显著差异。在18-24岁的人群中,电子烟的流行率增加了五倍,从2014年的5.0%增加到2024年的25.0% (PR = 5.00; 95% CI = 4.18-5.91),到2023年将超过吸烟。尽管吸烟率下降(25.3%至19.9%;PR = 0.79; 95% CI = 0.71-0.88),但这导致了尼古丁使用的总体增加(26.1%至36.5%;PR = 1.40; 95% CI = 1.29-1.53)。在这一年龄组中,纯电子烟成为最常见的尼古丁使用方式,而尼古丁袋的使用量也有所增加。在18-24岁的吸烟者中,每日吸烟率大幅下降,并转向非每日吸烟。在25-44岁的成年人中也观察到类似的趋势,尽管随着年龄的增长变化较小。在年龄较大的年龄组(≥45岁)中,每日吸烟率略有下降,而电子烟的吸烟率逐渐上升,但尼古丁使用的总体变化不大。大多数吸电子烟的成年人都有吸烟史,但从未经常吸烟的比例有所增加,尤其是18-24岁的人群(4.3%至34.3%;PR = 7.98; 95% CI = 4.56-26.2)。结论:尼古丁使用的代际变化正在英国发生。在过去十年中,年轻人中尼古丁的使用量有所上升,但他们越来越多地从每天吸烟转向电子烟或非日常吸烟。虽然老年人也显示出远离日常吸烟的趋势,但传统的吸烟模式在这一群体中仍然更为普遍。这些趋势表明,电子烟可能会逐渐取代吸烟,成为尼古丁消费的主要形式。
{"title":"The changing face of nicotine use in England: Age-specific annual trends, 2014 to 2024.","authors":"Sarah E Jackson, Lion Shahab, Vera Buss, Harry Tattan-Birch, Sharon Cox, Eve Taylor, Jamie Brown","doi":"10.1111/add.70243","DOIUrl":"https://doi.org/10.1111/add.70243","url":null,"abstract":"<p><strong>Aims: </strong>To examine age-specific trends in patterns of nicotine use in England between 2014 and 2024, including types of products used, exclusive and dual use of smoking and vaping, smoking frequency and the smoking history of those who vape.</p><p><strong>Design: </strong>Repeat monthly cross-sectional analysis of data from a nationally representative survey (the Smoking Toolkit Study).</p><p><strong>Setting: </strong>England, 2014-2024.</p><p><strong>Participants: </strong>217 433 adults (≥18y).</p><p><strong>Measurements: </strong>Prevalence of (non-medicinal) nicotine use overall and by product type (combustible tobacco, e-cigarettes, heated tobacco products and nicotine pouches), exclusive and dual use of smoking and vaping, daily versus non-daily smoking and smoking history among those who vape. Estimates were stratified by age group (18-24, 25-34, 35-44, 45-54, 55-64, ≥65y) and year. Prevalence ratios (PR) with 95% confidence intervals (CI) were calculated to quantify relative changes in prevalence from 2014 to 2024.</p><p><strong>Findings: </strong>Nicotine use patterns varied markedly by age. Among 18-24-year-olds, vaping prevalence increased fivefold, from 5.0% in 2014 to 25.0% in 2024 (PR = 5.00; 95% CI = 4.18-5.91), surpassing smoking by 2023. This contributed to an overall increase in nicotine use (26.1% to 36.5%; PR = 1.40; 95% CI = 1.29-1.53), despite declining smoking rates (25.3% to 19.9%; PR = 0.79; 95% CI = 0.71-0.88). In this age group, exclusive vaping became the most common mode of nicotine use, while nicotine pouch use also increased. Daily smoking declined substantially among 18-24-year-olds who smoked, with a shift toward non-daily smoking. Similar trends were observed among adults aged 25-44, though changes were smaller with increasing age. In older age groups (≥45), daily smoking declined modestly while vaping rose gradually, but there was little overall change in the prevalence of nicotine use. Most adults who vaped had a history of smoking, but the proportion who had never regularly smoked increased, particularly among 18-24-year-olds (4.3% to 34.3%; PR = 7.98; 95% CI = 4.56-26.2).</p><p><strong>Conclusions: </strong>Generational shifts in nicotine use are occurring in England. Nicotine use has risen among young adults over the past decade, but they are increasingly moving away from daily cigarette smoking towards vaping or non-daily smoking. While older adults have also shown movement away from daily smoking, traditional smoking patterns remain more prevalent in this group. These trends suggest vaping may gradually replace smoking as the dominant form of nicotine consumption.</p>","PeriodicalId":109,"journal":{"name":"Addiction","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2025-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145699558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Addiction
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1